Downloads
-
Risk Control | Bulk Filling Application
4/25/2024
Learn about a bulk filling system that enables you to achieve risk control, accuracy, and superior product recovery in your fill and finish operations.
-
Sterility Testing For A Connected Era
4/25/2024
This pump combines state-of-the-art hardware with sophisticated, user-friendly software to offer compliant, paperless documentation and reporting.
-
21 CFR Part 11 Compliance Checklist For A Universal Pump
4/25/2024
This checklist provides a detailed look at the requirements of 21 CFR Part 11 and highlights how the Sterisart® Universal | Gen 4 - Advanced supports your efforts to meet these regulatory demands.
-
Integrating Quality Processes And Documentation After A Merger
4/25/2024
If your company is undergoing a merger, you must juggle operations while ensuring minimal disruptions. You'll need a holistic view of QMS and SOPs to harmonize procedures.
-
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
4/25/2024
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.
- Bulk Filling Of Drug Substance | Accurate Aliquoting 4/24/2024
-
Clone, Strain, And Viral Construct Screening Executed For You
4/24/2024
Evaluate your clones, strains, and viral constructs in our bioreactors with flexible scale out.
Benefits
Select the best clone by evaluating larger experimental cohorts
Make the most informed, data-driven selection by leveraging our fleet of 250mL and 5L Culture bioreactors to screen your clones, strains and viral constructs.
Defer your capital equipment spend
Evaluate your clones, strains and viral constructs without the need for new capital equipment.
Transparent, real-time data provided by a team of experts
Painless technology transfer with live data relayed via our cloud-connected systems. We have >95% success rate with >22,000 runs successfully executed.
-
Leverage Bioreactor Capacity When You Need It With Culture Bioreactors
4/24/2024
Gain access to Culture bioreactors when you need rapid overflow experimental capacity.
Benefits
Progress studies faster
Run overflow projects and conduct parallel experiments with Culture to reduce time and alleviate bottlenecks.
Stay agile in your capacity planning
Scale your workload at Culture according to your current needs. Respond rapidly to surging demands.
Eliminate your capital equipment spend
Leverage Culture’s facility quickly to avoid building out lab space, spending capital on equipment, and hiring specialized staff.
-
NK Cell Therapies: How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach
4/24/2024
We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.
-
Evaluating CAR T-Cell Therapy Vascular Recruitment, Trafficking, And Killing
4/24/2024
Learn about a more human-relevant platform that enables researchers to assess the trafficking and killing efficiency of immunotherapy as well as the proof-of-concept of immuno-oncology co-therapy.